The purpose of the CFAR Developmental Core is to stimulate the growth of AIDS-related research at Case Western Reserve University and its affiliates by fostering translational basic/clinical research developing experimental technologies whose application will advance AIDS-related research, promoting interactions with other Centers on the Case Western Reserve University campus. A Developmental Core administrative structure has been established to distribute and monitor the use of developmental funds through a variety of mechanisms including (1) investigator initiated feasibility studies, (2) request for specific applications, (3) new technology development, (4) faculty recruitment, (5) state-of-the-art core development, (6) CFAR supplement applications, and (7) inter-center coordination. As a result of Developmental Core activities over a three year period, 12 new members have joined the CFAR, 5 manuscripts have been published, 5 national research grants totaling $2.9 million in direct costs, (including 1 minority supplement grant) have been funded, two new faculty members with a focus on AIDS-related research have been recruited to Case Western Reserve University, an ELIspot technology has been patented by Case Western Reserve University and provided as a service by a new CFAR Cytokine Core, thre other CFAR Cores have been enhanced, and several inter-center program initiatives have been developed. Developmental Core funds of $150,000/year are requested for years 06-10 to be used to support the Developmental Core programs as outlined above. In year 06, $75,000 will be used for faculty recruitment and the remained used to support investigator initiated feasibility studies and core development. In year 06 and in subsequent years, developmental Core funds will be distributed at the discretion of the CFAR leadership on a basis where the funds may have the greatest impact in stimulating AIDS-related research activities.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Freeman, Michael L; Lederman, Michael M; Gianella, Sara (2016) Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection. Curr HIV/AIDS Rep 13:10-9
Veazey, R S; Pilch-Cooper, H A; Hope, T J et al. (2016) Prevention of SHIV transmission by topical IFN-β treatment. Mucosal Immunol 9:1528-1536
Hirsch, Christina S; Rojas, Roxana; Wu, Mianda et al. (2016) Mycobacterium tuberculosis Induces Expansion of Foxp3 Positive CD4 T-cells with a Regulatory Profile in Tuberculin Non-sensitized Healthy Subjects: Implications for Effective Immunization against TB. J Clin Cell Immunol 7:
Althoff, Keri N; Rebeiro, Peter F; Hanna, David B et al. (2016) A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts. J Int AIDS Soc 19:20707
Hrecka, Kasia; Hao, Caili; Shun, Ming-Chieh et al. (2016) HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins. Proc Natl Acad Sci U S A 113:E3921-30
Valadkhan, Saba; Gunawardane, Lalith S (2016) lncRNA-mediated regulation of the interferon response. Virus Res 212:127-36
Reyes-Rodriguez, Angel L; Reuter, Morgan A; McDonald, David (2016) Dendritic Cells Enhance HIV Infection of Memory CD4(+) T Cells in Human Lymphoid Tissues. AIDS Res Hum Retroviruses 32:203-10
Li, Jonathan Z; Etemad, Behzad; Ahmed, Hayat et al. (2016) The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30:343-53
Gianella, Sara; Letendre, Scott (2016) Cytomegalovirus and HIV: A Dangerous Pas de Deux. J Infect Dis 214 Suppl 2:S67-74
Klein, Marina B; Althoff, Keri N; Jing, Yuezhou et al. (2016) Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis 63:1160-1167

Showing the most recent 10 out of 435 publications